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Inflammatory atherosclerosis is increased in subjects with type 1 diabetes mellitus (T1DM). Normally high-density lipoproteins
(HDL) protect against atherosclerosis; however, in the presence of serum amyloid-A- (SAA-) related inflammation this property
may be reduced. Fasting blood was obtained from fifty subjects with T1DM, together with fifty age, gender and BMI matched









-SAAweremeasured by ELISAs. Compared to control subjects, SAAwas increased in T1DM subjects, nonsignificantly in
serum (𝑃 = 0.088), and significantly in HDL
2
(𝑃 = 0.003) andHDL
3
(𝑃 = 0.005). When the T1DM group were separated according
to mean HbA1c (8.34%), serum-SAA and HDL
3
-SAA levels were higher in the T1DM subjects with HbA1c ≥ 8.34%, compared to
when HbA1c was <8.34% (𝑃 < 0.05). Furthermore, regression analysis illustrated, that for every 1%-unit increase in HbA1c, SAA




, respectively, independent of BMI. HsCRP did not differ between groups (𝑃 > 0.05).
This cross-sectional study demonstrated increased SAA-related inflammation in subjects with T1DM that was augmented by poor
glycaemic control. We suggest that SAA is a useful inflammatory biomarker in T1DM, which may contribute to their increased
atherosclerosis risk.
1. Introduction
Patients with type 1 diabetes mellitus (T1DM) have an
elevated risk of coronary atherosclerosis and coronary heart
disease (CHD) that is not explained by conventional risk
factors [1]. In contrast to patients with type 2 diabetesmellitus
(T2DM), their typical lipid profile is normal or even appar-
ently better than the general population, with increased high-
density lipoprotein- (HDL-) cholesterol and decreased low-
density lipoprotein- (LDL-) cholesterol and triglycerides [2].
However, these relatively simple lipid measurements poten-
tially mask more subtle lipoprotein abnormalities, including
disorders of lipoprotein function that might contribute to
atherosclerosis in T1DM.
Serum amyloid-A (SAA) is an inflammatory protein that
potentially contributes to dysfunctional HDL and progres-
sion of atherosclerosis. SAA has been detected in atheroscle-
rotic lesions particularly in foam cells, is thought to be
implicated in CHD [3] and may also indirectly cause plaque
destabilization—an independent risk factor for cardiovascu-
lar disease (CVD) [4].
Studies investigating serum-SAA in subjects with T1DM
have been inconclusive, some reporting increased levels [5]
and others no difference [6]. However, to date, no studies





, in subjects with T1DM. There are several
reasons for investigating SAA that is associated with HDL.
Firstly, serum-SAA is reflective of both acute and chronic
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inflammation and, therefore, is influenced by short-term
fluctuations in inflammation [7]. Secondly, SAA that is not
associated with HDL is liable to proteolytic cleavage [8],
which further influences its serum levels. Thirdly, as HDL
has an approximate 4-day half-life in the circulation [9],
SAA associated with this lipoprotein is more stable and thus
more reflective of chronic low-grade inflammation. Finally
and most importantly, because HDL function is impaired
by SAA within the particle rather than in serum [10–12],
direct measurement of HDL-associated SAA is necessary to
demonstrate that it may be of pathological significance in
T1DM.
Therefore, investigation of SAA in HDL subfractions in
T1DM enhances our knowledge of its usefulness as a marker
of inflammation and may also provide evidence of a mech-
anistic link between inflammation and atherosclerosis/CVD





in patients with T1DM and compared to
well-matched control group. Further analysis was carried out
to determine the contribution of glycaemic control on these
variables.
2. Materials and Methods
2.1. Study Population. Patients with T1DM (𝑛 = 50) were
recruited from the Diabetes Database in Tallaght Hospital,
Dublin, Ireland, and were not reported to have preexisting
CVD. Subjects without diabetes were recruited by local
advertisement or were relatives of the T1DM patients. The
inclusion criteria for subjects in the T1DM group were as
follows: T1DM, between 20 and 45 years of age, and BMI
less than 30 kg/m2, while the inclusion criteria for the control
group were as follows: nondiabetic, between 20 and 45 years
of age, and BMI less than 30 kg/m2. All subjects gave their
written signed consent to the study, which was approved by
the Research Ethics Committee of the Adelaide and Meath
Hospital and St. James’ Hospital (Dublin, Ireland).
2.2. Blood Processing. Blood was collected into standard
serum tubes by the vacuette system and was allowed to
sit at room temperature for a period of 30mins to allow
clotting. Serum was obtained by centrifugation at 3000 rpm
for 15mins at 4∘C. The serum supernatant was removed and
frozen in 1.3mL aliquots in a −80∘C freezer, until required for
further analysis.
2.3. Primary Laboratory Analysis. Baseline measurements
included fasting serum levels of glucose, total cholesterol,
triglycerides, HDL cholesterol, and LDL cholesterol, which
were measured using standard enzymatic assays on an auto-
mated ILab-600 biochemical analyser (Cobas Roche Diag-
nostics, West Sussex, UK). HbA1c was measured in serum by
ion exchange HPLC and high-sensitivity C-reactive protein
(hsCRP) wasmeasured by an enzyme linked immunosorbent
assay (ELISA) using a commercial available kit (BioCheck
Inc., Foster City, USA). Height (cm) and weight (kg) were
collected using a stadiometer and calibrated scales and used
to determine BMI (kg/m2). These primary laboratory analy-
ses were carried out in the laboratories of Tallaght Hospital,
Dublin.









were harvested from freshly thawed serum by rapid
ultracentrifugation, according to the method of McPherson
et al. [13]. This is a 3-step, 6-hour long procedure.






metrically using a commercial version of the Bradford assay
(Bio-Rad, Hemel Hempstead, UK), as previously described





. Apo AI concentration was
determined by single radial immunodiffusion, as previously
described [13].










available ELISA procedure (Invitrogen, KHA0011), which
detects human-SAA1 and SAA2.The analysis was performed
on a Grifols TRITURUS ELISA system (Italy), as per the
manufacturer’s instructions, with the following modifica-
tions. Serum was diluted 1 : 150, HDL
2
1 : 10 and HDL
3
1 : 100.
The intra- and interassay precision of this assay were both
<8%. This kit did not cross-react with a wide range of other
proteins, including CRP, TNF-𝛼, and IL-6.
2.7. Statistical Analysis. Statistical analyses were performed
using SPSS (Statistical Package for the Social Sciences) Statis-
tics version 21. Variables were assessed for normality and
logarithmically transformed where required. Between-group
analyses were analysed by independent t-test for normal
(𝑛 = 49) versus T1DM subjects (𝑛 = 50) (described as
comparison 1), and between T1DM subjects when separated
according to HbA1c; that is, the T1DM group was sepa-
rated into two groups according to mean HbA1c (<8.34%
(68mmol/mol) 𝑛 = 24 or ≥8.34% (68mmol/mol) 𝑛 = 26).
This secondary analysis is described as comparison 2. The
relationship betweenHbA1c and SAAwas further assessed by
linear regression. Correlations were determined by Pearson’s
coefficient. All variables were summarised as mean (standard
deviation, SD) when normally distributed and as geometric
mean (interquartile range) when normally distributed after
logarithmic transformation. Significance was set as 𝑃 ≤ 0.05.
3. Results
3.1. Subject Characteristics. Subjects with hsCRP > 10mg/L
were removed from the analyses (𝑛 = 1 in control group) as
this is suggestive of an active infection/inflammation and is
in accordance with American Heart Association Guidelines
[14].
Subject characteristics are shown in Table 1. These illus-
trate that when control subjects were compared to overall
T1DM subjects (comparison 1), BMI, age, gender, total-
cholesterol, and HDL-cholesterol were comparable between
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the groups (𝑃 > 0.05 for all analyses), while triglycerides
and LDL-cholesterol were lower in T1DM (𝑃 ≤ 0.05 for both
analyses). As was to be expected, fasting plasma glucose and
HbA1c were higher in T1DM subjects (𝑃 ≤ 0.001 for both
analyses).Therewere a small number of subjects in the T1DM
groupwhowere receiving statin therapy (5/50), while none of
the control subjects were receiving lipid lowering therapy.
To explore the effect of glycaemic control in T1DM, we
performed a further analysis where the T1DM group was
subdivided into patients with HbA1c < (𝑛 = 24) or ≥ (𝑛 = 26)
the median value (8.34%; 68mmol/mol). The results for this
analysis are presented as comparison 2 in Table 1, where BMI,
age, gender, fasting glucose, triglycerides, HDL-cholesterol,
and LDL-cholesterol were similar between the two T1DM
groups (𝑃 > 0.05 for all analyses). However, total cholesterol
was lower in the T1DM group with <8.34% HbA1C (𝑃 <
0.05). As anticipated HbA1c was lower in the T1DM subjects
in the group with HbA1c < 8.34%, compared to the T1DM
subjects with HbA1c ≥ 8.34% (𝑃 ≤ 0.001).





. The results illustrated that compared to control sub-
jects, total protein was significantly higher in HDL
2
(242
(90) versus 277 (86) mg/L; 𝑃 = 0.047) and significantly
lower in HDL
3
(2720 (793) versus 2410 (614) mg/L; 𝑃 =
0.033) in the overall T1DM group (comparison 1). Analysis
in comparison 2 demonstrated that the difference in HDL
2
protein resulted from higher levels in the T1DM group with
HbA1c ≥ 8.34%, compared to T1DM group with HbA1c <
8.34% (295 (92) versus 259 (76) mg/L; 𝑃 < 0.05), while the
difference in HDL
3
protein resulted from lower protein levels
in T1DM group with HbA1c < 8.34%, compared to the T1DM
group with HbA1c ≥ 8.34% (2271 (588) versus 2538 (620)





were comparable between the control and T1DM groups in
comparison 1 (HDL
2
, 162 (86) versus 146 (51) mg/L; 𝑃 =
0.255: HDL
3
, 1590 (690) versus 1583 (344) mg/L; 𝑃 = 0.951).





groups with <8.34% or ≥8.34%HbA1c, comparison 2 (HDL
2
,
141 (56) versus 150 (48) mg/L; 𝑃 = 0.508: HDL
3
, 1575 (356)
versus 1591 (338) mg/L; 𝑃 = 0.869).




Serum Analyses. Serum-hsCRP did not differ between the
groups in comparison 1 or 2 (𝑃 = 0.162 and 𝑃 = 0.355,
resp., Table 2). Although serum-SAA appeared higher in the
overall T1DMgroup from comparison 1, this only approached
significance compared to the control group (𝑃 = 0.088).
However, in comparison 2, serum-SAA was statistically
higher in the T1DM group with HbA1c ≥ 8.34%, compared
to the T1DM group HbA1c < 8.34% (𝑃 = 0.031).
HDL Analyses. Compared to the control group, the protein




was statistically higher in the overall T1DM group from
comparison 1 (𝑃 < 0.05, for both analyses). Comparison 2
illustrated that protein and nonprotein standardised HDL
2
-
SAA, although appeared higher in the T1DM group with
HbA1c ≥ 8.34%, it was not statistically different compared to
the T1DM group with HbA1c < 8.34% (𝑃 = 0.096 and 0.085,
resp.). However, both protein and nonprotein standardised
HDL
3
-SAA was statistically higher in the T1DM group with
HbA1c ≥ 8.34%, compared to the T1DM group with HbA1c <
8.34% (𝑃 = 0.028 and 0.019, resp.).
3.4. Relationship between HbA1c and SAA. The relationship
between HbA1c and SAA was further examined by linear
regression analysis. This revealed a positive relationship





SAA (Figures 1(a) and 1(b), resp.; 𝑃 < 0.001 for both
analyses), where every 1% unit increase in HbA1c was
associated with an estimated 20% (CI; 8–33%) increase in
HDL
2
-SAA and an estimated 23% (CI; 10–37%) increase in
HDL
3
-SAA. This relationship was further examined when
we excluded the control group from this analysis. Here





; 𝑟 = 0.306, 𝑃 = 0.098: HDL
3
;
𝑟 = 0.452, 𝑃 = 0.027). No relationship was found between
HbA1c and serum-SAA (𝑟 = 0.187; 𝑃 = 0.110). BMI, age,
and gender did not impact on our model, meaning that they
were not included in our regression analyses.
3.5. Correlations between SAA and hsCRP with Subject Char-
acteristics. There was a strong positive correlation between





0.001 for both correlations, Table 3). In addition, the presence





-SAA, although this was only significant for
the HDL subfractions (𝑃 = 0.093, 0.014 and 0.011, resp.). BMI
was positively correlated with serum-SAA and HDL
3
-SAA
(𝑃 = 0.002 for both correlations). Fasting plasma glucose,





-SAA (𝑃 > 0.05 for all correlations). hsCRP
was moderately correlated with serum-SAA (𝑃 = 0.038,
Table 3) and negatively correlated with age (𝑃 = 0.007).
HsCRP did not correlate with the presence of T1DM, glucose,
BMI, or gender (𝑃 > 0.05 for all correlations, Table 3) or with
HbA1c (𝑟 = 0.212; 𝑃 = 0.075).
4. Discussion
This is the first reported study to examine SAA in HDL in






genic properties of HDL particles include their pivotal role
in reverse cholesterol transport [15], as well as antioxidant
[16] and anti-inflammatory effects [17]. However, in the
presence of SAA-related inflammation, these antiatherogenic
properties are impaired [18–20]. Following release into the
circulation, SAA associates with HDL, particularly HDL
3
[21], which can augment atherogenesis, as SAA enhances
the binding of HDL to the arterial wall [22]. Furthermore,
dysfunctional HDL displays reduced reverse cholesterol
transport and antioxidant capabilities [23]. In the current
4 Journal of Diabetes Research
Table 1: Subject characteristics for comparison 1 and comparison 2.
Characteristic












BMI (kg/m2) 26.4 (3.5) 26.0 (3.9) 0.686 25.0 (3.5) 27.0 (4.1) 0.062
Age (years) 39.4 (10.1) 35.8 (8.3) 0.095 36.8 (9.1) 35.0 (7.5) 0.451
Gender (male : female) 17 : 32 18 : 32 0.836 9 : 15 9 : 17 0.836
Fasting glucose (mmol/L) 5.05 (4.60, 5.30) 9.89 (6.30, 14.60) ≤0.001 9.05 (5.20, 12.80) 10.63 (6.58, 14.85) 0.279
HbA1C (%) 5.3 (5.1, 5.5) 8.3 (7.4, 8.8) ≤0.001 7.4 (6.8, 8.0) 9.2 (8.6, 9.7) ≤0.001
HbA1c (mmol/mol) 34 (32, 37) 68 (57, 72) ≤0.001 57 (51, 64) 76 (70, 83) ≤0.001
Total cholesterol (mmol/L) 4.92 (0.86) 4.60 (0.84) 0.065 4.36 (0.83) 4.83 (0.80) 0.048
Triglycerides (mmol/L) 1.31 (0.77) 1.04 (0.39) 0.050 0.98 (0.34) 1.09 (0.44) 0.330
HDL cholesterol (mmol/L) 1.41 (0.34) 1.50 (0.41) 0.204 1.43 (0.52) 1.57 (0.28) 0.231
LDL cholesterol (mmol/L) 2.99 (0.84) 2.62 (0.68) 0.032 2.48 (0.57) 2.75 (0.76) 0.157
Statin therapy (number) 0 5 NA 1 4 NA
ACE Inhibitors (number) 0 5 NA 2 3 NA
Results expressed as mean (SD) or when data was not normally distributed as geometric mean (interquartile range).
Table 2: Serum hsCRP and Serum, HDL2 and HDL3 SAA concentration.
Analyate












Serum-hsCRP (mg/L) 1.97 (1.00, 2.38) 2.89 (1.00, 4.40) 0.162 2.56 (1.00, 2.30) 3.24 (1.30, 4.93) 0.355
Serum-SAA (𝜇g/L) 16241 (7275, 17645) 23837 (8133, 40737) 0.088 15885 (8060, 18945) 30706 (7984,47986) 0.031
Protein-standardised SAA
HDL2 (𝜇g/mg protein) 3.00 (0.97, 4.12) 5.63 (1.65, 7.63) 0.003 4.97 (1.41, 4.42) 6.23 (2.06, 9.94) 0.096
HDL3 (𝜇g/mg protein) 3.48 (1.37, 3.55) 5.95 (2.31, 9.57) 0.005 4.50 (1.18, 5.01) 7.34 (2.35, 12.29) 0.028
Nonprotein standardised SAA
HDL2 (𝜇g/L) 690 (242, 951) 1674 (379, 1990) 0.004 1260 (357, 1408) 2055 (541, 2589) 0.085
HDL3 (𝜇g/L) 8951 (3326, 8966) 15972 (4625, 23331) 0.005 10362 (3883, 13315) 21151 (6846, 33534) 0.019
Results expressed as mean (SD) or when data was not normally distributed as geometric mean (interquartile range).
study, SAA was increased by 53% in HDL
2
and 58% in HDL
3
in subjects with T1DM. This SAA had been standardised to





, compared to the control subjects. These differences
were small compared to differences in SAA and, therefore,
were unlikely to have significantly influenced the HDL-SAA
results. However, to ensure this was not the case we also
included the nonprotein standardised SAA results, where the
difference in HDL-SAA between the groups was maintained.
To examine the relationship between glycaemic con-
trol and HDL-SAA levels, we separated the overall T1DM
group according to mean HbA1c (< or ≥8.34%), where the
differences identified in comparison 1 was, in the main,
driven by higher HDL-SAA levels in the T1DM subjects
with poor glycaemic control (HbA1c ≥ 8.34%; comparison
2). Although prolonged poor glycaemic control is associated
with chronic inflammation [24], the mechanisms underlying
the association between increased SAA and T1DM are not
clear. However, there is evidence that SAA promotes insulin
resistance [25] and that intensive insulin therapy can reduce
SAA levels [4], whilst the insulin-sensitising and antioxidant
drug troglitazone is reported to lower SAA in T2DM subjects
[26]. In support of the concept that glycaemic control and
inflammation are linked, the current study further illustrated
that glycaemic control was closely associated with increased
SAA-related inflammation, where for every 1% unit increase





-associated SAA of 20% and 23%, respectively. How-
ever, and contrary to this, Helio¨vaara et al. [6] reported
that serum-SAA did not respond to glycaemic intervention
to lower HbA1c in T1DM subjects, although we suggest
that this may not have been the case had they measured
HDL-SAA. Additionally, this group [6] only reported a
0.8% decrease in HbA1c following intervention, which may
have been insufficient to mediate a statistical effect. Finally,
their small subject population (24 subjects with T1DM) may





















































r = 0.469; P < 0.001
(b)





Table 3: Correlations between SAA and subject characteristics.
Serum-SAA
𝑟 =; 𝑃 =
HDL2-SAA
𝑟 =; 𝑃 =
HDL3-SAA
𝑟 =; 𝑃 =
hsCRP
𝑟 =; 𝑃 =
Serum-SAA — 0.779; ≤0.001 0.888; ≤0.001 0.234; 0.038
T1DM status 0.191; 0.093 0.246; 0.014 0.256; 0.011 0.206; 0.062
BMI 0.349; 0.002 0.044; 0.663 0.302; 0.002 0.196; 0.076
Fasting plasma glucose 0.063; 0.730 0.134; 0.457 0.113; 0.539 −0.124; 0.267
Age 0.070; 0.541 −0.056; 0.585 −0.011; 0.917 −0.294; 0.007
Gender 0.197; 0.082 0.139; 0.169 0.155; 0.129 0.077; 0.491
T1DM status: control = 0; type 1 = 1.
have minimised their power to detect a change in serum-
SAA, especially as serum-SAA is reported to display a large
standard deviation (as discussed in detail below).
Overall, and to the author’s knowledge, this is the first
study to demonstrate an association between glycaemic
control and levels of HDL-SAA in subjects with T1DM, and
we suggest that a possible mechanism may be a result of an
“underinsulinised” liver in poorly controlled T1DM subjects.
With regard to our serum-SAA results, although serum-
SAA was higher in the poorly controlled T1DM subjects
(HbA1c ≥ 8.34%) in comparison 2 (𝑃 = 0.031), between-
group differences were less clear-cut between the overall
T1DM subjects and the control subjects from comparison
1 (𝑃 = 0.088). We can suggest several reasons for this
anomaly; firstly, the T1DM subjects with better glycaemic
control (HbA1c < 8.34%; comparison 2) may have impacted
on the T1DM result in comparison 1. Secondly, as serum-SAA
displays a large variation, as illustrated by our wide spread of
interquartile ranges reported in Table 2, this would minimise
our statistical power. In fact, a large standard deviation
was suggested to be responsible for the nonsignificantly
higher levels of serum-SAA reported in 24 T1DM subjects,
compared to 16 control subjects [6]. Further credence to this
conceptmay be provided byZhi et al. [5], where they reported
statistically higher serum-SAA levels in a very large T1DM
cohort (1139 T1DM subjects versus 848 control subjects).
Furthermore, although Basu et al. [27] reported that serum-
SAA was not different in a T1DM/control group comparison
with similar subject numbers to our current study (38 T1DM
subjects versus 41 control subjects), we suggest that this
may be due to their control group being under greater
inflammatory stress, as both serum-SAA and hsCRP were
higher in their control group.
Overall, we suggest that the apparently lower sensitivity
of serum-SAA, compared to the HDL subfractions, possibly
reflects differences between acute and chronic inflammation.
As described under Introduction, serum-SAA is indicative
of both acute and chronic inflammation [7] and, therefore,
more subject to daily fluctuations, which may impact greatly
when subject numbers are small. In contrast, since HDL has
a half-life of approximately 4 days [9], SAA associated with
this lipoprotein is predicted to be more stable and, therefore,
a more useful marker of chronic low grade inflammation in
both small and large cohorts.
6 Journal of Diabetes Research
5. Conclusions
In summary, this cross-sectional study has highlighted HDL-
SAA as a sensitive biomarker to detect increased inflam-
mation in subjects with T1DM and provides a potential
mechanistic explanation for accelerated atherosclerosis of
this condition. Longitudinal studies are required to explore
whether SAA changes in response to improved glycaemic
control in T1DM.
Study Limitations. There are several limitations to this study.
Firstly, we must address the fact that several of our T1DM
patients were on statin therapy (10%), which is known to
lower SAA levels, especially under conditions of heightened
inflammation [28]. However, this was also the group in which
SAA was increased, suggesting that SAA may have been
even higher had none of the T1DM subjects been on this
therapy. Secondly, several of our T1DM subjects were taking
ACE inhibitors, which are reported to increase SAA [29].
However, although this may appear, in part, to have driven
the difference between the T1DM and control cohorts, this
could not be the case as ACE inhibitor use was similar in
the two T1DM cohorts, while SAA levels were different. This
would suggest that it was unlikely that the ACE inhibitors had
influenced SAA levels in this study. Thirdly, our lack of an
ability to detect statistically significant differences in serum-
SAA between our overall T1DM group and the control group
may be due to our relatively small subject numbers and the
fact that SAA is known to display a large variation between
subjects. Fourthly, we did not examine SAA associated with
VLDL and LDL, which has recently been shown to be
increased in subjects with documented atherosclerosis [30].
Fifthly, due to our small subject numbersmeant that it was not
possible to correlate SAA with established CVD risk factors,
such as intimalmedia thickness. Sixthly, we also acknowledge
that it is desirable for HbA1c to be ≤7% to reduce the vascular
complications of diabetes and to indicate a better-controlled
T1DM cohort [31]. However, in the current study only 5 of
our 50 T1DM patients had an HbA1c of ≤7%, meaning that
it was not possible to carry out such a sub analysis. Finally,
we must address the differing HDL-protein concentrations
identified between the control and T1DM groups, which
we suggest may be related to changes in HDL-associated
proteins, relative to T1DM status. In the case of HDL
2
,
this may be related, in part, to the increased SAA protein
identified in the T1DM subjects, and, in the case ofHDL
3
, this
may be related to changes in the concentration of other HDL-
associated proteins, such as paraoxonase-1, which readily
associates with HDL
3






hsCRP: High-sensitivity C-reactive protein
SAA: Serum amyloid A
T1DM: Type 1 diabetes mellitus.
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